Experimental assessment of a phosphor model for estimating the relative extrinsic efficiency in radioluminescent detectors

Optimising phosphor screens in dose detectors or imaging sensor designs is a cumbersome and time- consuming work normally involving specialised measuring equipment and advanced modelling. It is known that crucial optical parameters of the same phosphor may vary within a wide range of values. The aim of this work was to experimentally assess a simple previously published model where the case specific optical parameters (scattering and absorption) are instead represented by a fixed, single parameter, the light extinction factor, ξ. The term extrinsic efficiency, N, of a phosphor is also introduced, differing from the common denotation “absolute efficiency”, after noting that unknown factors (such as temperature dependence) can have an influence during efficiency estimations and hence difficult to claim absoluteness. N is expressed as the ratio of light energy emitted per unit area at the phosphor surface to incident x-ray energy fluence. By focusing on ratios and relative changes in this study, readily available instruments in a Medical Physics Department (i.e. a photometer) could be used.The varying relative extrinsic efficiency for an extended range of particle sizes (7.5 and 25 µm) and layer thicknesses (220 to 830 µm) were calculated in the model from the input parameters: the mean particle size of the phosphor, the layer thickness, the light extinction factor and the calculated energy imparted to the layer. In-house manufactured screens (Gd₂O₂S:Tb) were used for better control of design parameters. The model provided good qualitative agreement to experiment with quantitative deviations in relative extrinsic efficiency within approximately 2%.     

Protosappanin‐A and oleanolic acid protect injured podocytes from apoptosis through inhibition of AKT‐mTOR signaling

Protosappanin‐A (PrA) and oleanolic acid (OA), which are important effective ingredients isolated from Caesalpinia sappan L., exhibit therapeutic potential in multiple diseases. This study focused on exploring the mechanisms of PrA and OA function in podocyte injury. An in vitro model of podocyte injury was induced by the sC5b‐9 complex and assays such as cell viability, apoptosis, immunofluorescence, quantitative real‐time polymerase chain reaction, and western blot were performed to further investigate the effects and mechanisms of PrA and OA in podocyte injury. The models of podocyte injury were verified to be successful as seen through significantly decreased levels of nephrin, podocin, and CD2AP and increased level of desmin. The sC5b‐9‐induced podocyte apoptosis was inhibited in injured podocytes treated with PrA and OA, accompanied by increased protein levels of nephrin, podocin, CD2AP, and Bcl2 and decreased levels of desmin and Bax. The p‐AKT/p‐mTOR levels were also reduced by treatment of PrA and OA while AKT/mTOR was unaltered. Further, the effects of PrA and OA on injured podocytes were similar to that of LY294002 (a PI3K‐AKT inhibitor). PrA and OA were also seen to inhibit podocyte apoptosis and p‐AKT/p‐mTOR levels induced by IGF‐1 (a PI3K‐AKT activator). Our data demonstrate that PrA and OA can protect podocytes from injury or apoptosis, which may occur through inhibition of the abnormal activation of AKT‐mTOR signaling.     

The protective effects of grape seed procyanidin B2 against asporin mediates glycated low‐density lipoprotein induced‐cardiomyocyte apoptosis and fibrosis

The progression of diabetic cardiomyopathy is related to cardiomyocyte dysfunction and apoptosis. Our previous studies showed that asporin (ASPN) was significantly increased in the myocardium of db/db mice through proteomics, and grape seed procyanidin B2 (GSPB2) significantly inhibited the expression of ASPN in the heart of db/db mice. We report here that ASPN played a critical role in glycated low‐density lipoproteins (gly‐LDL) induced‐cardiomyocyte apoptosis. We found that gly‐LDL upregulated ASPN expression. ASPN increased H9C2 cardiomyocyte apoptosis with down‐regulation of Bcl‐2, upregulation of transforming growth factor‐β1, Bax, collagen III, fibronectin, and phosphorylation of smad2 and smad3. However, GSPB2 treatment reversed ASPN‐induced impairments in H9C2 cardiomyocytes. These results provide evidence for the cardioprotective action of GSPB2 against ASPN injury, and thus suggest a new target for fighting against diabetic cardiomyopathy.     

细胞程序性死亡因子家族分子在细胞凋亡中的调控作用

细胞程序性死亡因子(programmed cell death,PDCD)是一类与肿瘤发展相关并在进化上高度保守的蛋白质。PDCD家族由多个成员构成。其中,研究较为深入的包括PDCD1、PDCD2、PDCD4、PDCD5、PDCD6、PDCD7、PDCD8及PDCD10。PDCD在人类的各组织及细胞中广泛分布,其主要功能是对细胞凋亡的调控。目前研究发现,PDCD家族成员可通过不同信号通路实现对肿瘤细胞活力的调控,且某些家族成员的缺失或过表达都会引起机体发生病变,证明其在多种疾病当中具有重要作用。本文汇总了PDCD1、PDCD2、PDCD4、PDCD5、PDCD6、PDCD7、PDCD8、PDCD9、PDCD10、PDCD11、PDCD12的基因结构与蛋白质结构,介绍了各家族成员在细胞程序性死亡过程中的关系,并总结目前所报道的PDCD家族成员在肿瘤,以及多种疾病中所发挥的调控作用,以期帮助科研工作者了解其在细胞凋亡中的作用,以及为肿瘤和相关疾病发生发展的分子机制提供参考。     

Peroxiredoxin 2 deficiency reduces white adipogenesis due to the excessive ROS generation

Reactive oxygen species (ROS) act as signaling molecules to regulate various cell functions. Numerous studies have demonstrated ROS to be essential for the differentiation of adipocytes. Peroxiredoxins (Prxs) are a ubiquitous family of antioxidant enzymes in mammalian cells. Prx2 is present in the cytoplasm and cell membranes and demonstrates ROS scavenging activity. We focused on Prx2 involvement in regulating adipogenesis and lipid accumulation and demonstrated that Prx2 expression was upregulated during adipocyte differentiation. In addition, the silencing of Prx2 (shPrx2) inhibited adipogenesis by modulating adipogenic gene expression, and cell death was enhanced via increased ROS production in shPrx2‐3T3‐L1 cells. These results demonstrate that shPrx2 triggers adipocyte cell death and weakens adipocyte function via ROS production. Taken together, our data suggest the participation of Prx2 in adipocyte function and differentiation. Our results also imply that the downregulation of Prx2 activity could help prevent obesity. Overall, findings support the development of ROS‐based therapeutic solutions for the treatment of obesity and obesity‐related metabolic disorders.     

Silencing LINC00504 inhibits cell proliferation,invasion as well as migration and promotes cell apoptosis in lung cancer cells via upregulating miR-876-3p

LINC00504 acts as an oncogene and associates with unfavorable prognosis in patients with lung cancer. Silencing LINC00504 may be a promising strategy for treatment of lung cancer and its effects were firstly investigated in lung cancer cells this study. The gene expression level of miR-876-3p as well as LINC00504 were measured via PCR assay. The cell proliferation was investigated through Cell Counting Kit-8 (CCK-8) assay and colony formation assay. Flow cytometry was applied for detection of cell apoptosis. Wound healing and transwell assay were performed for measurement of cell migration and invasion respectively. The apoptosis related protein expressions were measured by western blot. Luciferase report assay was conducted for verification the target gene. LINC00504 was higher expressed in five types of lung cancer cells studied herein when compared with the control normal cells. LINC00504 knockdown exerted inhibitory effects on cell apoptosis, cell migration as well as cell invasion and promoted cell apoptosis. All the effects mentioned above were counteracted by miR-876-3p inhibitor. Silencing LINC00504 possessed anti-proliferation, repression of cell invasion as well as migration and pro-apoptosis effects via targeting up-regulation of miR-876-3p in lung cancer cells, proving the new therapeutic targets and highlighting the potential application in future diagnosis and treatment in lung cancer.